Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Single-Arm Study of Perampanel (Fycompa) in Adult-Type Diffuse Glioma (CNS WHO Grade 2-3)
jRCT1061250057Phase 2Recruiting
- Start
- Oct 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perampanel in Adult-type diffuse glioma, CNS WHO grade 2 (LGG), diffuse midline glioma (DMG) and epilepsy. Primary endpoint: Ki-67 index reduction ≥20%. Started Oct 2025; status: recruiting.
02
Drugs
perampanel
03
Conditions
Adult-type diffuse glioma, CNS WHO grade 2 (LGG)diffuse midline glioma (DMG)epilepsy
Beyond the preview
Go deeper on jRCT1061250057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061250057.